camrelizumab camrelizumab camrelizumab (shr-1210) (inn) is an anti-pd-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and hodgkin lymphoma. camrelizumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetpd1clinical dataother namesshr-1210atc codenoneidentifierscas number1798286-48-2unii73096e137e this drug is being developed by jiangsu hengrui medicine co., ltd. as of 2019, camrelizumab is undergoing phase ii/iii trials.